PT  - JOURNAL ARTICLE
AU  - Diana Valentina Tudor
AU  - Ioana Bâldea
AU  - Mihai Lupu
AU  - Teodor Kacso
AU  - Eniko Kutasi
AU  - Andreea Hopârtean
AU  - Roland Stretea
AU  - Adriana Gabriela Filip
TI  - COX-2 as a potential biomarker and therapeutic target in melanoma
AID  - 10.20892/j.issn.2095-3941.2019.0339
DP  - 2020 Feb 15
TA  - Cancer Biology and Medicine
PG  - 20--31
VI  - 17
IP  - 1
4099  - http://www.cancerbiomed.org/content/17/1/20.short
4100  - http://www.cancerbiomed.org/content/17/1/20.full
SO  - Cancer Biol Med2020 Feb 15; 17
AB  - With a constantly increasing incidence, cutaneous melanoma has raised the need for a better understanding of its complex microenvironment that may further guide therapeutic options. Melanoma is a model tumor in immuno-oncology. Inflammation represents an important hallmark of cancer capable of inducing and sustaining tumor development. The inflammatory process also orchestrates the adaptative immunosuppression of tumor cells that helps them to evade immune destruction. Besides its role in proliferation, angiogenesis, and apoptosis, cyclooxygenase-2 (COX-2) is a well-known promoter of immune suppression in melanoma. COX-2 inhibitors are closely involved in this condition. This review attempts to answer two controversial questions: is COX-2 a valuable prognostic factor? Among all COX-2 inhibitors, is celecoxib a suitable adjuvant in melanoma therapy?